🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. GC1107

    Green Valley (Shanghai) Pharmaceuticals Co.,

    Bacterial Infections

    phase 3 mab completed

    1 trial

  2. GEMCITABINE, Mrtx1719 matching placebo, PACLITAXEL ALBUMIN-BOUND, MRTX1719

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. GENTAMICINE PANPHARMA 80 mg, solution injectable, Gentamicin Placebo, Metronidazole Biogaran 500 mg Placebo, Natriumchlorid-Lösung 0,9 % Deltamedica, Injektionslösung, METRONIDAZOLE BIOGARAN 500 mg, comprimé pelliculé

    Pari Pharma GmbH

    Acute mesenteric ischemia

    phase 3 small molecule active

    1 trial

  4. GLUCOPHAGE 500 mg tabletki powlekane, Placebo

    Bial Portela & Companhia S.A.

    papillary thyroid carcinoma

    phase 3 small molecule active

    1 trial

  5. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  6. GS-100

    Grace Therapeutics

    NGLY1 Deficiency

    phase 3 gene therapy active

    1 trial

  7. GTX-104

    Grace Therapeutics

    Aneurysmal Subarachnoid Hemorrhage (aSAH)

    phase 3 small molecule active

    1 trial

  8. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Pain

    phase 3 small molecule completed

    3 trials

  9. GW-1000-02

    Jazz Pharmaceuticals Ireland Limited

    Multiple Sclerosis

    phase 3 small molecule completed

    4 trials

  10. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizure in Participants With Tuberous Sclerosis Complex

    phase 3 small molecule terminated

    1 trial

  11. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    5 trials

  12. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Tuberous Sclerosis Complex

    phase 3 small molecule completed

    2 trials

  13. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Rett Syndrome

    phase 3 small molecule terminated

    2 trials

  14. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Seizures Associated With EMAS

    phase 3 small molecule terminated

    1 trial

  15. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Infantile Spasms

    phase 3 small molecule completed

    2 trials

  16. GWP42003-P 20 mg/kg/Day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 3 small molecule completed

    3 trials

  17. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Chronic Migraine

    phase 3 small molecule active

    1 trial

  18. Galcanezumab, Placebo to match LY2951742

    Eli Lilly Co.

    Migraine

    phase 3 small molecule active

    1 trial

  19. Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed), Placebo formulation of Gardasil, Gardasil 9 suspension for injection in a pre-filled syringe. Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed)

    The George Institute

    Patients with primary HPV high-grade squamous intra-epithelial lesions (HSIL) at any site (vulvar VIN, vaginal VaIN, penile (PeIN), cervical CIN, anal AIN) at the time of treatment.

    phase 3 small molecule active

    1 trial

  20. Gazyva Placebo, Gazyvaro 1,000 mg concentrate for solution for infusion.

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 3 small molecule active

    1 trial

  21. Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial

  22. Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  23. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  24. Givinostat 50 mg capsules, RIVAROXABAN , ACETYLSALICYLIC ACID , Givinostat 100 mg capsules, HYDROXYCARBAMIDE, ENOXAPARIN , -, Givinostat 75 mg capsules, DABIGATRAN ETEXILATE

    Italfarmaco S.p.A.

    JAK2V617F-positive high-risk Polycythemia Vera

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources